Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| J. P. Garrahan Hospital | UNKNOWN |
| Hospital Italiano de Buenos Aires | OTHER |
| Royal Children's Hospital | OTHER |
| Medical University Innsbruck |
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to investigate the incidence, current management practices, and outcomes in pediatric patients with HAC after liver transplantation.
Research question:
The burden of participation is considered to be minimal, and limited to the questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Conservative treatment | |||
| Surgical revascularization | |||
| Endovascular revascularization | |||
| Re-transplantation |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Graft survival | Graft survival is defined as a functioning graft from transplantation to the end of follow-up data, re-transplantation, or death, whichever occurs first. | 1-1-2001 and 1-1-2023 |
| Patient survival | Patient survival is defined from the date of the primary LT until date of death. Causes of re-transplantation or death will be recorded. | 1-1-2001 and 1-1-2023 |
| Measure | Description | Time Frame |
|---|---|---|
| Technical success | Technical success is defined as the success of the intervention in re-establishing the arterial blood flow to the liver and will be assessed by each individual center. | 1-1-2001 and 1-1-2023 |
| Primary and secondary patency |
Not provided
Inclusion criteria:
Exclusion criteria:
N/A
Not provided
Not provided
Any pediatric patient diagnosed with HAC and treated for HAC (at age <18 years) after pediatric liver transplantation between 1-1-2002 and 1-1-2023
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Medical Center Groningen | Groningen | 9700 RB | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38866577 | Derived | Li W, van der Doef HPJ, Wildhaber BE, Marra P, Bravi M, Pinelli D, Minetto J, Dip M, Sierre S, de Santibanes M, Ardiles V, Uno JW, Hardikar W, Bates S, Goh L, Aldrian D, Seisenbacher J, Vogel GF, Neto JS, Antunes da Fonseca E, Magalhaes Costa C, Ferreira CT, Nader LS, Farina MA, Dajani KZ, Parente A, Bigam DL, Liang TB, Bai X, Zhang W, Gonsorcikova L, Fronek J, Bohus S, Franchi-Abella S, Gonzales E, Guerin F, Junge N, Baumann U, Richter N, Hartleif S, Sturm E, Rajakannu M, Palaniappan K, Rela M, Pawaria A, Rajakrishnan H, Surendran S, Kumar M, Agarwal S, Gupta S, Asthana S, Bandewar V, Raichurkar K, Spada M, Monti L, Alterio T, Yanagi Y, Uchida H, Komine R, Evans H, Carr-Boyd P, Duncan D, Stefanowicz M, Latka-Grot J, Kolesnik A, Broering DC, Raptis DA, Ann H Marquez K, Mali V, Aw M, Beretta M, Van der Schyff F, Quintero-Bernabeu J, Mercadal-Hally M, Larrarte K M, Andres AM, Hernandez-Oliveros F, Frauca E, Casswall T, Jorns C, Delle M, Gupte G, Sharif K, McGuirk S, Superina R, Caicedo JC, Jaramillo C, Bitterfeld L, Kastenberg Z, Shah AA, Domenick B, Acord MR, Mazariegos GV, Soltys K, DiNorcia J, Antala S, Florman SS, Buchholz BM, Herden U, Fischer L, Dierckx RAJO, Hartog H, Bokkers RPH. Incidence, management and outcomes in hepatic artery complications after paediatric liver transplantation: protocol of the retrospective, international, multicentre HEPATIC Registry. BMJ Open. 2024 Jun 12;14(6):e081933. doi: 10.1136/bmjopen-2023-081933. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| ID | Term |
|---|---|
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| OTHER |
| Hospital Sirio-Libanes | OTHER |
| Hospital Santo Antonio | UNKNOWN |
| Faculty of Medicine & Dentistry, University of Alberta | UNKNOWN |
| Zhejiang University | OTHER |
| Thomayer University Hospital | OTHER |
| Hôpital Bicêtre | UNKNOWN |
| University Children's Hospital | OTHER |
| Hannover Medical School | OTHER |
| Universitätsklinikum Hamburg-Eppendorf | OTHER |
| Dr Rela Institute and Medical Centre | UNKNOWN |
| Amrita Institute of Medical Sciences & Research Center | OTHER |
| Max Super Speciality Hospital | OTHER |
| Aster CMI Hospital | UNKNOWN |
| Papa Giovanni XXIII Hospital | OTHER |
| Bambino Gesù Children's Hospital | UNKNOWN |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
| Auckland City Hospital | OTHER_GOV |
| Children's Memorial Health Institute | UNKNOWN |
| King Faisal Specialist Hospital & Research Center | OTHER |
| National University Hospital, Singapore | OTHER |
| Wits Donald Gordon Medical Centre | UNKNOWN |
| La Paz University Hospital | UNKNOWN |
| Vall d'Hebron Barcelona Hospital Campus | UNKNOWN |
| Karolinska Institutet | OTHER |
| University Hospital, Geneva | OTHER |
| Birmingham Women's and Children's Hospital | UNKNOWN |
| Primary Children's Hospital | OTHER |
| Children's Hospital of Philadelphia | OTHER |
| Children's Hospital Pittsburgh | UNKNOWN |
| Recanati-Miller Transplantation Institute, Mount Sinai Hospital | UNKNOWN |
| Ann & Robert H Lurie Children's Hospital of Chicago | OTHER |
| RenJi Hospital | OTHER |
Not provided
Not provided
Not provided
Primary patency is defined as the time between the index treatment and re-intervention intended to restore patency in patients with a restenosis or re-occlusion. Secondary patency is the time between the index treatment and failure to re-establish flow by means of re-intervention. In case of re-transplantation or death due to other reasons, the patients will be censored if the treated vessel is patent. Kaplan-Meier curves will be plotted to visualize primary and secondary patency rates at various times after treatment for HAC, including 1, 3, 5, 10, 15 and 20 years.
| 1-1-2001 and 1-1-2023 |
| Intra- and post-procedural complications | Procedural complications will be categorized into two main groups: transplant complications and procedural complications related to endovascular or surgical revascularization for HAC. Within these groups, intra-procedural complications predominantly consist of vascular issues, such as thrombosis, stenosis, compression, dissection, and rupture. In contrast, post-procedural complications encompass a broader range of issues, such as infection, rejection, bleeding, and vascular and biliary complications, including anastomotic stricture, non-anastomotic strictures, bile leak, biloma, or cholangitis. Re-interventions addressing both intra- and post-procedural complications will also be recorded. | 1-1-2001 and 1-1-2023 |
| Anticoagulant therapy after transplantation and after interventions | Anticoagulant therapy after transplantation and after interventions for HAC will be assessed according to the management practices of each participating site (center specific) and individual patient data (patient specific). Details about each anticoagulation regimen, including the specific anticoagulant, duration of anticoagulation, and upper and lower limits of target values, such as international normalized ratio, anti-factor Xa, and activated partial thromboplastin time, will be recorded. Patient-specific management will be documented for patients with HAC. | 1-1-2001 and 1-1-2023 |
| Center specific screening protocol | Local screening protocols to assess HAC after LT, such as the routine post-operative Doppler ultrasound policy, will be documented. Whether HAC screening is consistent for patients with and without risk factors will also be examined. The frequency of preferred radiological screening investigations within 2 weeks after LT will be determined, considering various risk factors. | 1-1-2001 and 1-1-2023 |
| Center specific diagnostic criteria | The diagnostic criteria section will cover the types of HAC, non-invasive radiological criteria, and interventional radiological criteria during invasive angiography. The center's definition of technical success after interventional radiological treatment will also be recorded. | 1-1-2001 and 1-1-2023 |
| Center specific radiological follow up | The radiological follow-up section will assess whether follow-up protocols are the same for all interventions or specific to each intervention type. The imaging methods and frequencies of radiological follow-up for different treatment modalities will be determined. Additionally, the experience years and level of seniority of the interventional radiologist will be recorded. | 1-1-2001 and 1-1-2023 |
| Incidence | The incidence of HAC will be determined by dividing the total number of patients diagnosed with HAC between 1st of January 2002 and 1st of January 2023, who had undergone LT between 1st of January 2002 and 1st of January 2022, by the total number of patients who underwent LT at pediatric age between 1st of January 2002 and 1st of January 2022. The study will present the overall incidence of HAC during the 20-year period of 2002 to 2022, as well as the incidence during specific 5-year intervals, namely 2002 to 2007, 2007 to 2012, 2012 to 2017, and 2017 to 2022, for each complication. | 1-1-2001 and 1-1-2023 |
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |